Consistent with PRECAM study, our study also dedicated focus on MSS/pMMR tumor patients, showing that when combined with PD-1 antibody, TNT-like chemoradiotherapy resulted in better pCR rates in comparison with concurrent chemoradiotherapy with a PD-1 antibody. The gene discussed is PDCD1; the disease is neoplasm.